Q32 Bio (Q32 Bio) Debt-to-EBITDA : -0.34 (As of Mar. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Q32 Bio Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Q32 Bio's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $4.65 Mil. Q32 Bio's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $15.50 Mil. Q32 Bio's annualized EBITDA for the quarter that ended in Mar. 2024 was $-58.88 Mil. Q32 Bio's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 was -0.34.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Q32 Bio's Debt-to-EBITDA or its related term are showing as below:

QTTB' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -1.15 Med: -1.07 Max: -0.14
Current: -0.5

During the past 3 years, the highest Debt-to-EBITDA Ratio of Q32 Bio was -0.14. The lowest was -1.15. And the median was -1.07.

QTTB's Debt-to-EBITDA is ranked worse than
100% of 279 companies
in the Biotechnology industry
Industry Median: 1.35 vs QTTB: -0.50

Q32 Bio Debt-to-EBITDA Historical Data

The historical data trend for Q32 Bio's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Q32 Bio Debt-to-EBITDA Chart

Q32 Bio Annual Data

Trend

Dec21

Dec22

Dec23

Debt-to-EBITDA

-0.14

-1.15

-1.07

Q32 Bio Quarterly Data
	Dec21	Sep22	Dec22	Mar23	Sep23	Dec23	Mar24
Debt-to-EBITDA	Get a 7-Day Free Trial			-1.44	-	N/A	-0.50	-0.34

Competitive Comparison of Q32 Bio's Debt-to-EBITDA

For the Biotechnology subindustry, Q32 Bio's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Q32 Bio's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Q32 Bio's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Q32 Bio's Debt-to-EBITDA falls into.

Q32 Bio Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Q32 Bio's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(1.416	+	49.424)	/	-47.756
	=	-1.06

Q32 Bio's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(4.648	+	15.499)	/	-58.88
	=	-0.34

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Mar. 2024) EBITDA data.

Q32 Bio (NAS:QTTB) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Q32 Bio Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Q32 Bio's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Q32 Bio (Q32 Bio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Q32 Bio Inc (NAS:QTTB) » Definitions » Debt-to-EBITDA

Comparable Companies

Traded in Other Exchanges

N/A

Address

830 Winter Street, Waltham, MA, USA, 02451

Website

https://www.q32bio.com

Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body's first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function. ADX-097, the lead product candidate from Q32's complement inhibitor platform, is a humanized anti-C3d monoclonal antibody fusion protein.

Q32 Bio (Q32 Bio) Headlines

From GuruFocus

Q32 Bio Appoints Lee Kalowski as President & Chief Financial Officer

By PRNewswire • 04-03-2024